2023
Association of SGLT‐2 Inhibitors With Treatment Satisfaction and Diabetes‐Specific and General Health Status in Adults With Cardiovascular Disease and Type 2 Diabetes
Ding Q, Spatz E, Bena J, Morrison S, Levay M, Lin H, Grey M, Edwards N, Isaacs D, West L, Combs P, Albert N. Association of SGLT‐2 Inhibitors With Treatment Satisfaction and Diabetes‐Specific and General Health Status in Adults With Cardiovascular Disease and Type 2 Diabetes. Journal Of The American Heart Association 2023, 12: e029058. PMID: 37655510, PMCID: PMC10547320, DOI: 10.1161/jaha.122.029058.Peer-Reviewed Original ResearchConceptsSodium-glucose cotransporter 2 inhibitorsGeneral health statusCardiovascular disease typesType 2 diabetesTreatment satisfactionDiabetes-specific qualityCardiovascular diseaseHealth statusDisease typeProspective observational study designPatient-reported health statusInverse probabilityNoninsulin antidiabetic medicationsSGLT-2i useSGLT-2i usersTreatment-weighted analysisCotransporter 2 inhibitorsSGLT-2 inhibitorsDiabetes treatment satisfactionObservational study designGreater reductionAntidiabetic medicationsDiabetes medicationsSecondary outcomesSymptom burden
2022
CARDIOVASCULAR DISEASE AND TYPE 2 DIABETES: TREATMENT SATISFACTION, QUALITY OF LIFE AND DIABETES RELATED SYMPTOMS WHEN RECEIVING SODIUM GLUCOSE COTRANSPORTER 2 INHIBITOR VERSUS OTHER NONINULIN DIABETES MEDICATIONS
Ding Q, Spatz E, Isaacs D, Bena J, Morrison S, Levay M, West L, Combs P, Albert N. CARDIOVASCULAR DISEASE AND TYPE 2 DIABETES: TREATMENT SATISFACTION, QUALITY OF LIFE AND DIABETES RELATED SYMPTOMS WHEN RECEIVING SODIUM GLUCOSE COTRANSPORTER 2 INHIBITOR VERSUS OTHER NONINULIN DIABETES MEDICATIONS. Journal Of The American College Of Cardiology 2022, 79: 1547. DOI: 10.1016/s0735-1097(22)02538-4.Peer-Reviewed Original Research